Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keynote 042: Pembrolizumab vs Chemotherapy in PD-L1 Positive Advanced NSCLC
NCT02220894Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02220894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220894.